3-叔-丁基-2-吡唑啉-5-酮 | 29211-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 中文名称: 3-叔-丁基-2-吡唑啉-5-酮
• 英文名称: 3-tert-butyl-1H-pyrazol-5(4H)-one
• 英文别名: 5-tert-butyl-2,4-dihydro-3H-pyrazol-3-one；3-tert.-Butyl-pyrazolon-(5)；3-tert-Butyl-2-pyrazolin-5-one；3-tert-butyl-1,4-dihydropyrazol-5-one
• CAS: 29211-68-5
• 化学式: C₇H₁₂N₂O
• mdl: MFCD00051760
• 分子量: 140.185
• InChiKey: VDNOHRWEOSDGQX-UHFFFAOYSA-N

物化性质

• 熔点：
  208 °C
• 密度：
  1.11±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，未有已知危险反应。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933199090
• 安全说明：
  S22,S24/25

SDS

Name:	3-(tert-Butyl)-4 5-dihydro-1H-pyrazol-5-one TECH Material Safety Data Sheet
Synonym:	3-tert-Butyl-2-pyrazoline-5-on
CAS:	29211-68-5

Section 1 - Chemical Product MSDS Name:3-(tert-Butyl)-4 5-dihydro-1H-pyrazol-5-one TECH Material Safety Data Sheet
Synonym:3-tert-Butyl-2-pyrazoline-5-on

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
29211-68-5	3-(tert-Butyl)-4,5-dihydro-1H-pyrazol-		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 29211-68-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 208 - 210 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H12N2O
Molecular Weight: 140.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 29211-68-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(tert-Butyl)-4,5-dihydro-1H-pyrazol-5-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 29211-68-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 29211-68-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 29211-68-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴邻苯二酚 、 3-叔-丁基-2-吡唑啉-5-酮 在 laccase from Agaricus bisporus 作用下， 以 aq. phosphate buffer 为溶剂， 反应 17.0h， 以96%的产率得到3'-bromo-4'-(3-tert-butyl-5-hydroxy-1H-pyrazol-4-yl)benzene-1',2'-diol
  参考文献：
  名称：

  Laccase-catalyzed reaction of 3-tert-butyl-1H-pyrazol-5(4H)-one with substituted catechols using air as an oxidant

  摘要：

  The laccase-catalyzed reaction of 3-tert-butyl-1H-pyrazol-5(4H)-one with a number of catechols and aerial oxygen as an oxidant selectively affords 4-substituted 3-tert-butyl-1H-pyrazol-5-ol derivatives with yields ranging from 77 to 99%. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.03.023

文献信息

• Substituted Imidazopyridines as HDM2 Inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140179680A1

  公开（公告）日：2014-06-26

  The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的取代咪唑吡啶或其药用可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• NEPRILYSIN INHIBITORS
  申请人：Fleury Melissa

  公开号：US20150210690A1

  公开（公告）日：2015-07-30

  In one aspect, the invention relates to compounds having the formula I: where R 1 -R 6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

  在一个方面，该发明涉及具有以下式I的化合物： 其中R1-R6如规范中定义，或其药学上可接受的盐。这些化合物具有神经肽酶抑制活性。在另一个方面，该发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY
  申请人：FOO Shi Yin

  公开号：US20120122844A1

  公开（公告）日：2012-05-17

  The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R 1 , R 2 , R 3 , R 5 , X, A 3 , B 1 , s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

  本发明提供了中性内切肽酶抑制剂的使用，用于制造用于治疗、改善和/或预防造影剂诱导性肾病的药物。该发明还涉及使用化合物Formula I中的化合物：其中R1、R2、R3、R5、X、A3、B1、s和n在此处定义，用于治疗、改善和/或预防造影剂诱导性肾病。本发明进一步提供了用于治疗、改善和/或预防造影剂诱导性肾病的药理活性剂的组合。
• Versatile three-component synthesis of 2′-amino-1,2-dihydrospiro[(3H)-indole-3,4′-(4′H)-pyran]-2-ones
  作者：V. Yu. Mortikov、Yu. M. Litvinov、A. A. Shestopalov、L. A. Rodinovskaya、A. M. Shestopalov

  DOI：10.1007/s11172-008-0338-7

  日期：2008.11

  2-dihydrospiro[(3H)-indole-3,4′-(4′H)-pyran]-2-ones has been suggested consisting in the three-component reaction of isatins, cyanoacetic acid derivatives, and α-methylenecarbonyl compounds (β-dicarbonyl compounds, activated phenols, and OH-substituted heterocycles) in ethanol in the presence of triethylamine as a catalyst. The reaction proceeds selectively to form spiro[(3H)-indole-3,4′-(4′H)-pyrans].

  一种合成 2'-amino-1,2-dihydrospiro[(3H)-indole-3,4'-(4'H)-pyran]-2-ones 的通用方法包括在三组分中在三乙胺作为催化剂的存在下，靛红、氰乙酸衍生物和 α-亚甲基羰基化合物（β-二羰基化合物、活化酚和 OH 取代的杂环）在乙醇中的反应。该反应选择性地进行以形成螺[(3H)-吲哚-3,4'-(4'H)-吡喃]。
• Synthesis of heterocyclic compounds from 4-formylpyrazoles
  作者：V. Yu. Mortikov、L. A. Rodinovskaya、A. E. Fedorov、A. M. Shestopalov、P. A. Belyakov

  DOI：10.1007/s11172-014-0451-8

  日期：2014.2

  Formylation of pyrazole and 2,5-dimethylpyrazole gave a number of pyrazole-containing aldehydes, which can be used to obtain chromenes, tetrahydrochromenes, 1,4-dihydropyrano[2,3-c]pyrazoles, pyrano[3,2-c]chromenes, thiochromeno[4,3-b]pyrans, pyrano[3,2-c]-quinolines, and thiazolo[3,2-a]pyridines.

  吡唑和2,5-二甲基吡唑的甲酰化反应生成了多种含吡唑的醛，这些醛可用于合成克罗美烯、四氢克罗美烯、1,4-二氢吡喃[2,3-c]吡唑、吡喃[3,2-c]克罗美烯、硫克罗美烯[4,3-b]吡喃、吡喃[3,2-c]喹啉和噻唑[3,2-a]吡啶。

表征谱图